

Claims:

1. A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of:
- 5 (a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysine and arginine; and
- (b) a single layer of coating on said core which
- 10 comprises a layer of an enteric coating agent applied from an organic solvent based system.
2. A pharmaceutical composition of omeprazole as defined in claim 1 wherein said core is further ^{u 2} comprised essentially of a surface active agent, and a binder and said pharmaceutical composition is formed into a compressed tablet.
- 15
3. A pharmaceutical composition as defined in claim 1 wherein said core is further comprised essentially of a an inert core component, a surface active agent and a binder and said pharmaceutical composition is pelleted.
- 20
4. A pharmaceutical composition of omeprazole as defined in claim 2 wherein the acid resistant component is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic
- 25
- 30 acid/methacrylic acid methyl esters.
5. A pharmaceutical composition of omeprazole as defined in claim 3 wherein the acid resistant component is selected from the group consisting of cellulose
- 35 acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate,

carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters.

6. A pharmaceutical composition of omeprazole as
5 defined in claim 1 wherein the enteric coating agent also includes an inert processing aid.

7. A pharmaceutical composition of omeprazole as
defined in claim 1 wherein the enteric coating agent
10 around the core includes from 5 to 55wt% by weight of the coating of an inert processing aid.

8. A pharmaceutical composition of omeprazole as
defined in claim 1 which includes a sodium lauryl
15 sulfate as the surface active agent. *112 added basis*

9. A pharmaceutical dosage formulation which consists essentially of:

- (a) a tablet core comprising omeprazole, a binder, an
20 alkaline agent selected from the group consisting of arginine or lysine, a filler; and
(b) an enteric coating agent around said core, said enteric coating comprising hydroxypropylmethyl cellulose phthalate and talc.

25

10. A pharmaceutical composition as defined in claim 3
wherein the core contains a non-pariel sugar seed.

11. A pelleted pharmaceutical dosage formulation which
30 consists essentially of:

- (a) a core comprising a non-pariel sugar seed coated with drug layer composition comprising omeprazole, a binder, an alkaline agent selected from the list consisting of arginine and lysine, a filler and a
35 surface active agent; and
(b) an enteric coating agent around said core, said

page 6 #

add A1

enteric coating comprising hydroxypropylmethyl
cellulose phthalate and talc which is applied from
an organic solvent based system.

09763831.07.11.01